New leukemia combo aims for higher remission rates

NCT ID NCT07512700

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two treatments for acute monocytic leukemia, a blood cancer. About 204 people aged 14 to 60 will get either a new drug combo (venetoclax plus CACAG) or standard chemotherapy (3+7). The goal is to see which approach leads to more complete remissions after one cycle.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MONOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute monocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MONOCYTIC LEUKEMIA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Air Force Medical Center, PLA
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chinese PLA General Hospital
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
PLA Strategic Support Force's Characteristic Medical Center
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••